Los Angeles, California 90025


Purpose:

The primary objective of the study is to test the incremental efficacy and outcomes of an aftercare program of Cognitive Behavioral Therapy combined with motivational therapy (CBT-MT) relative to treatment as usual (TAU) in improving depression, substance use, and healthcare outcomes in a population with drug dependence and comorbid major depressive disorder (MDD). The investigators expect that among drug-dependent patients with comorbid MDD, CBT-MT will yield better clinical outcomes relative to TAU in reducing depressive symptoms and substance use and improving healthcare outcomes during treatment. Secondary Objectives: 1. Test efficacy and outcomes of CBT-MT and TAU 2. Evaluate the differential effect of CBT-MT versus TAU on HIV-risk behavior of participants, 3. To evaluate the impact of cognitive functioning on treatment retention and outcomes, and 4. To explore additional psychosocial, demographic, and diagnostic factors (e.g., age, gender, education level, motivation for change, social support) that may be associated with treatment outcome and retention in this high need population. This study will include approximately 80 participants randomized to either 12 weeks of motivational therapy or treatment as usual. Both treatments will meet once weekly for 60 minutes. Participants will be recruited from the Adult Partial Hospitalization program at UCLA. During the active treatment phase, participants will attend clinic weekly for collection of data and urine specimens. 1. For those randomly assigned to CBT-MT, they will meet with a therapist in a group format for 60-minute sessions once weekly. a. Each CBT-MT session will begin with 20 minutes of motivational therapy (MT), followed by 40 minutes of CBT content. 2. Those randomly assigned to TAU, they will attend a weekly 60-minute Dual Recovery Anonymous self-help group.


Criteria:

Inclusion Criteria: 1. Age 18 or over 2. DSM-IV diagnosis of Substance Dependence (cannabis, stimulant, opioid, or prescription drug) or DSM-IV diagnosis of Alcohol Dependence and abuse of cannabis, stimulant, opioid, or prescription drug 3. DSM-IV diagnosis of lifetime Major Depressive Disorder (MDD) 4. BDI-II score of 13 or greater Exclusion Criteria: 1. Presence of life threatening or unstable medical illness 2. Lack of proficiency in English 3. Current homelessness (unless residing in a recovery home for which contact information can be provided) 4. Psychiatric symptoms warranting safety concerns or inpatient treatment, including acute suicide risk 5. Present diagnosis of Bipolar Disorder, Schizophrenia, or Schizoaffective Disorder.


NCT ID:

NCT01189799


Primary Contact:

Anne Bellows, MSW
Phone: 310-267-5232
Email: abellows@mednet.ucla.edu


Backup Contact:

N/A


Location Contact:

Los Angeles, California 90025
United States

Anne Bellows, MSW
Phone: 310-267-5232
Email: abellows@mednet.ucla.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: August 31, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.